FDA Orange Book · active-ingredient family
Penicillin g benzathine
Penicillin g benzathine is approved in 5 FDA applications, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:BICILLIN L-A · NDA 050141
5
Brand (NDA)
0
Generics (ANDA)
0
Listed patents
0
Exclusivity periods
Brand (NDA) products · injectable, suspension, tablet
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| BICILLIN L-ARLD×2 | KING PHARMS LLC | NDA 050141 | — | Approved Prior to Jan 1, 1982 | |
| BICILLIN L-A | WYETH AYERST | NDA 050131 | — | Approved Prior to Jan 1, 1982 | |
| PERMAPEN | CASPER PHARMA LLC | NDA 060014 | — | Approved Prior to Jan 1, 1982 | |
| BICILLIN | WYETH AYERST | NDA 050126 | — | Approved Prior to Jan 1, 1982 | |
| BICILLIN | WYETH AYERST | NDA 050128 | — | Approved Prior to Jan 1, 1982 |
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Penicillin g benzathine — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

